	Argatroban	PROTOCOL FOR ISOLATED HIT, HIT & HITTS IN PATIENTS WITH NORMAL HEPATIC FUNCTION (NON CATH LAB)
	Indication	Anticoagulant for prophylaxis or treatment of thrombosis in patients with Isolated HIT, HIT, HITTS (Heparin induced Thrombocytopenia/thrombosis syndrome)
	Contraindications	Overt major bleeding; argatroban should be avoided if LFT are greater than or equal to 3 times the upper limit of normal
	Diagnose of HIT	HIT antibody test Is used to diagonse HIT-2
	Baseline Labs	aPTT, PT/INR, Serum Creatinine, CMP, HCT, and platelets
	Monitoring	Platelets daily while on argatroban
	Monitoring	Guaiac all stools, gastroccult all emesis, visually check for hematuria or other bleeding. CALL PHYSICIAN FOR BLEEDING
		diately for any of the following: unexplained drop in blood pressure, development of hematoma, drop in hematocrit, significant bleed, flank pain, bright red urine or bruising
	Discontinue	All Heparin, Lovenox (enoxaparin), dalteparin (Fragmin)
	Discontinue	Discontinue warfarin until platelts are back to baseline or > 100,000 (preferably when count is 150,000)
	Discontinue	IM injections while on Argatroban, obtain physician order for alternative route
	Antidote	No antagonist is avialable to reverse the action of argatroban
	Transition to Warfarin	Start when platelet count > 100,000 (preferably when count is 150,000). No starting doses > 5 mg. Overlap with argatroban for at least 5 days.
	INR Monitoring	INR daily. If INR > 4 on combination therapy stop argatroban, repeat INR in 4-6 hours, if INR is less than therapeutic restart
	0	argatroban at previous rate. Repeat the procedure daily. Discontinue argatroban when two consecutive daily INRs are therapeutic on warfarin alone after therapy
		has overlapped for at least 5 days.
	aPTT Monitoring	Draw aPTT 2 hours and 6 hours after initiation of therapy and every 4 hours after any change in infusion rate until
	-	two consecutive PTT are therapeutic then draw PTT every 24 Hours
		If aPTT is greater than 100 seconds, stop argatroban, drawn aPTT every 2 hours unit aPTT within therapeutic range, restart argatroban at new rate
		All aPTTs should be run stat
	aPTT Goal	aPTT 40-83 seconds (round actual aPTT to closest whole number)
		Dosage adjustments based on aPTT see Argatroban Rates Changes Based on aPTT Chart
	Mixing instructions	Dilute each 2.5ml vial with 250ml of 0.9% Sodium Chloride Injection, 5% Dextrose Injection or Lactated Ringer's
		Injection to obtain a final concentration of 1mg/ml. The constituted solution must be mixed by repeated inversion
		of the diluent bag for 1 minute. Upon preparation, the solution may show slight, but brief haziness due to the
		formation of microprecipitates that rapidly dissolve upon mixing.
	Drug Amount	250 mg
	Volume	250 ml
	Final Concentration	1000 mcg/ml
		More concentrated solutions are not recommended as precipitation may occur.
	Starting Dose	2 mcg/kg/min
		Renal Dysfunction (creatinine clearanace less than 60 ml/min): Consider starting at 1 mcg/kg/min
		Liver Dysfunction: 0.5 mcg/kg/min (Hepatic Disease score greater than 6)
		Hepatic Disease Score and creatinine clearance calculators are available on the pharmacy web site under calculators
		If Liver Function Test are greater than 3 times upper limit of normal do not use argatroban
	Dosage Range	0.5-10 mcg/kg/min

Maximum Dose 10 mcg/kg/min

Patient Weight	Patient Weight	INITIAL DOSE (mcg/kg/min)														
(kg)	(lbs)	0.1	0.2	0.3	0.4	0.5	1	2	3	4	5	6	7	8	9	10
40	88	0.2	0.5	0.7	1	1.2	2.4	4.8	7	10	12	14	17	19	22	24
45	99	0.3	0.5	0.8	1.1	1.4	2.7	5	8	11	14	16	19	22	24	27
50	110	0.3	0.6	0.9	1.2	1.5	3	6	9	12	15	18	21	24	27	30
55	121	0.3	0.7	1	1.3	1.7	3.3	7	10	13	17	20	23	26	30	33
60	132	0.4	0.7	1.1	1.4	1.8	3.6	7	11	14	18	22	25	29	32	36
65	143	0.4	0.8	1.2	1.6	2	3.9	8	12	16	20	23	27	31	35	39
70	154	0.4	0.8	1.3	1.7	2.1	4.2	8	13	17	21	25	29	34	38	42
75	165	0.5	0.9	1.4	1.8	2.3	4.5	9	14	18	23	27	32	36	41	45
80	176	0.5	1	1.4	1.9	2.4	4.8	10	14	19	24	29	34	38	43	48
85	187	0.5	1	1.5	2	2.6	5	10	15	20	26	31	36	41	46	51
90	198	0.5	1.1	1.6	2.2	2.7	5	11	16	22	27	32	38	43	49	54
95	209	0.6	1.1	1.7	2.3	2.9	6	11	17	23	29	34	40	46	51	57
100	220	0.6	1.2	1.8	2.4	3	6	12	18	24	30	36	42	48	54	60
105	231	0.6	1.3	1.9	2.5	3.2	6	13	19	25	32	38	44	50	57	63
110	242	0.7	1.3	2	2.6	3.3	7	13	20	26	33	40	46	53	59	66
115	253	0.7	1.4	2.1	2.8	3.5	7	14	21	28	35	41	48	55	62	69
120	264	0.7	1.4	2.2	2.9	3.6	7	14	22	29	36	43	50	58	65	72
125	275	0.8	1.5	2.3	3	3.8	8	15	23	30	38	45	53	60	68	75
130	286	0.8	1.6	2.3	3.1	3.9	8	16	23	31	39	47	55	62	70	78
135	297	0.8	1.6	2.4	3.2	4.1	8	16	24	32	41	49	57	65	73	81
140	308	0.8	1.7	2.5	3.4	4.2	8	17	25	34	42	50	59	67	76	84
145	319	0.9	1.7	2.6	3.5	4.4	9	17	26	35	44	52	61	70	78	87
150	330	0.9	1.8	2.7	3.6	4.5	9	18	27	36	45	54	63	72	81	90
155	341	0.9	1.9	2.8	3.7	4.7	9	19	28	37	47	56	65	74	84	93
160	352	1	1.9	2.9	3.8	4.8	10	19	29	38	48	58	67	77	86	96
165	363	1	2	3	4	5	10	20	30	40	50	59	69	79	89	99
170	374	1	2	3.1	4.1	5	10	20	31	41	51	61	71	82	92	102
							R	ATE (ml/h	nr)							

			Based on aPTT					
			t for rate in ml/hr					
aPTT (Seconds)								
33 or less	34-39	40-83	84-96	97 or higher				
50% Increase	25% Increase	No Change	25% Decrease	50% Decrease				
		Rate Change						
f aPTT is greate	r than 100 seco	nds, stop arga	troban, drawn aPT	T every				
2 hours until aP	TT is within ther	apeutic range	, then restart argat	roban at new				
rate		apouno rungo	, chon rootart a gat	oball at lion				
ate								
Round the aPTT	to the closest w	hole number						

Marshall Pierce PharmD.